Cardiff Oncology (CRDF) Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiff Oncology in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CRDF shares.
View CRDF analyst ratings or view top-rated stocks.

3 brokerages have issued 1 year price targets for Cardiff Oncology's stock. Their CRDF share price forecasts range from $5.00 to $14.00. On average, they predict the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 370.6% from the stock's current price.
View analysts price targets for CRDF or view top-rated stocks among Wall Street analysts.

Cardiff Oncology's stock was trading at $1.40 on January 1st, 2023. Since then, CRDF shares have increased by 21.4% and is now trading at $1.70.
View the best growth stocks for 2023 here.

Cardiff Oncology saw a decrease in short interest in May. As of May 15th, there was short interest totaling 542,300 shares, a decrease of 12.1% from the April 30th total of 616,900 shares. Based on an average daily volume of 198,500 shares, the days-to-cover ratio is currently 2.7 days.
View Cardiff Oncology's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our CRDF earnings forecast.

Cardiff Oncology, Inc. (NASDAQ:CRDF) issued its quarterly earnings results on Thursday, May, 4th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.02. The company earned $0.08 million during the quarter, compared to analysts' expectations of $0.08 million. Cardiff Oncology had a negative trailing twelve-month return on equity of 35.70% and a negative net margin of 9,862.78%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include Sorrento Therapeutics (SRNE), Livongo Health (LVGO), Co-Diagnostics (CODX), Novavax (NVAX), Fortress Biotech (FBIO), Maxar Technologies (MAXR), Ontrak (OTRK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX) and Cassava Sciences (SAVA).

Cardiff Oncology trades on the NASDAQ under the ticker symbol "CRDF."

Cardiff Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (1.70%), Citigroup Inc. (1.46%), Assenagon Asset Management S.A. (0.88%), Renaissance Technologies LLC (0.74%), Two Sigma Advisers LP (0.32%) and Blair William & Co. IL (0.29%). Insiders that own company stock include Gary W Pace, James E Levine, John P Brancaccio, Lale White, Mark Erlander, Renee P Tannenbaum, Rodney S Markin and Vicki Kelemen.
View institutional ownership trends.

Shares of CRDF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRDF stock can currently be purchased for approximately $1.70.

Cardiff Oncology (NASDAQ:CRDF) has a market capitalization of $75.96 million and generates $390,000.00 in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

Cardiff Oncology's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The official website for the company is cardiffoncology.com. The company can be reached via phone at (858) 952-7570 or via email at ir@cardiffoncology.com.